-
Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report
Tai Zhao,
Yajin Wang,
Yuqing Du
Issue:
Volume 10, Issue 2, June 2022
Pages:
26-29
Received:
15 February 2022
Accepted:
15 March 2022
Published:
14 April 2022
Abstract: Primary retroperitoneal leiomyosarcoma originated from smooth muscle tissue or mesenchymal cells with the potential to differentiate into smooth muscle cells, showing aggressive growth, easy to recur and metastasize after operation, with a 5-year overall survival rate of 28% - 40%. Multidisciplinary comprehensive treatment based on surgery is an effective means of leiomyosarcoma, while radiotherapy is mainly aimed at subclinical lesions and residual lesions. There is no standard treatment for advanced retroperitoneal leiomyosarcoma. How to effectively prolong the survival time of patients is worth discussing. Aim: To determine the comprehensive treatment of retroperitoneal leiomyosarcoma based on surgery, and to explore the effective prolongation of the survival time of patients with advanced retroperitoneal leiomyosarcoma. Case Summary: A female with pelvic leiomyosarcoma survived for 70 months after surgery, postoperative radiotherapy, local ablation and chemoembolization. Finally, multiple metastases of lung and liver occurred, abdominal distension and fatigue was hospitalized. After oral administration of anlotinib 12mg q1-14d, she survived for 10 months. Conclusion: Leiomyosarcoma needs multidisciplinary comprehensive treatment based on surgery. Late-line anti angiogenesis therapy with arotinib can improve the quality of life of patients and effectively prolong the progression free survival of advanced patients because of its mild adverse reactions, good tolerance and Oral convenience.
Abstract: Primary retroperitoneal leiomyosarcoma originated from smooth muscle tissue or mesenchymal cells with the potential to differentiate into smooth muscle cells, showing aggressive growth, easy to recur and metastasize after operation, with a 5-year overall survival rate of 28% - 40%. Multidisciplinary comprehensive treatment based on surgery is an ef...
Show More
-
Prognostic Significance of Systemic Cholesterol Profile in Patients with Breast Cancer
Radhika Chowdary,
Raghu Ram Pillarisetti,
Vinod Kumar Verma,
Radhika Korabathina,
Syed Sultan Beevi
Issue:
Volume 10, Issue 2, June 2022
Pages:
30-33
Received:
28 March 2022
Accepted:
15 April 2022
Published:
25 April 2022
Abstract: Breast cancer ranks as the number one cancer among Indian females with survival as low as 66.1%. Relationship between cholesterol and breast cancer has triggered special interest due to their role in important cellular processes that steer toward carcinogenesis. The interplay between cholesterol and tumor development have been studied in experimental breast cancer models. However, epidemiological data reveal conflicting results, that need to be integrated and put into appropriate viewpoint. This study aims to investigate and corroborate the impact of total cholesterol (TC), triglyceride (TG), VLDL, LDL and HDL cholesterol on the disease-free and overall survival of patients with breast cancer. This study retrospectively analyzed 50 breast cancer patients who underwent radical surgery and attended follow-up visits at KIMS Hospitals. The blood lipid levels such as TC, TG, VLDL, LDL and HDL cholesterol were collected and analyzed from the database of Department of Laboratory Medicine. Potential prognostic factors including age, menopause, grade, receptor status, systemic cholesterol profile etc., were analyzed by univariate and multivariate analysis. TC less than 180mg/dL was associated with disease relapse in univariate analysis. TG, VLDL, LDL and HDL cholesterol were not significantly correlated either to disease-free or overall survival. Low systemic cholesterol level could be a significant prognostic factor for a shorter disease-free survival.
Abstract: Breast cancer ranks as the number one cancer among Indian females with survival as low as 66.1%. Relationship between cholesterol and breast cancer has triggered special interest due to their role in important cellular processes that steer toward carcinogenesis. The interplay between cholesterol and tumor development have been studied in experiment...
Show More
-
Sarcomatoid Carcinoma of the Gallbladder: A Case Report and Literature Review
Ting Xiong,
Shihua Liu,
Yuying Lei,
Liangliang Zhang,
Aixia Sui
Issue:
Volume 10, Issue 2, June 2022
Pages:
34-37
Received:
14 May 2022
Accepted:
2 June 2022
Published:
14 June 2022
Abstract: Sarcomatoid carcinoma of the gallbladder is a highly malignant tumor originating from totipotent mesenchymal stem cells, accounting for only 4.1% of gallbladder cancers. Its clinical manifestations are very similar to adenocarcinoma of the gallbladder, mainly presenting in the digestive tract. Surgical resection is currently the only possible cure for sarcomatoid carcinoma of the gallbladder. Due to the lack of effective diagnostic means at early stage, many patients have reached the middle and late stage of diagnosis, and the prognosis is often poor. In this paper, we present a case of a 52-year-old woman with advanced and rapidly progressing sarcomatoid carcinoma of the gallbladder causing obstructive cholangitis. She developed bone marrow suppression after immunotherapy combined with chemotherapy. The patient died after symptomatic and supportive treatment. This paper reports the whole process of diagnosis and treatment in this case of gallbladder sarcomatoid carcinoma, thus carring out a discussion based on relevant literaturea and providing a reference for treatment.
Abstract: Sarcomatoid carcinoma of the gallbladder is a highly malignant tumor originating from totipotent mesenchymal stem cells, accounting for only 4.1% of gallbladder cancers. Its clinical manifestations are very similar to adenocarcinoma of the gallbladder, mainly presenting in the digestive tract. Surgical resection is currently the only possible cure ...
Show More
-
Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer
Xinxin Duan,
Liuyi Yang,
Jie Zhou,
Ting Xiong,
Aixia Sui
Issue:
Volume 10, Issue 2, June 2022
Pages:
38-45
Received:
2 June 2022
Accepted:
16 June 2022
Published:
27 June 2022
Abstract: Pancreatic cancer is a digestive system tumor with high degree of malignancy. At present, systemic chemotherapy is the main treatment method. However, due to the difficulty in early diagnosis and easy spread of pancreatic cancer, the survival cycle of patients is short and the treatment effect is poor. 125I seed brachytherapy has obvious advantages in the treatment of malignant tumors, and has been widely used in the treatment of unresectable pancreatic cancer. Either used alone or combined with chemotherapy, the treatment of 125I seed brachytherapy can effectively relieve pain, improve life quality and prolong survival. However, there are few reports about the application status. This article reviews the current updates of 125I seed brachytherapy for resectable pancreatic cancer, and expounds the application status of 125I seeds brachytherapy in combination with monotherapy chemotherapy, dual drug chemotherapy, targeted therapy, immunity therapy, palliative surgery, external radiotherapy and traditional Chinese medicine. Based on the retrospective review, future directions of research and development of brachytherapy for unresectable pancreatic cancer is also proposed, to provide better treatment care for pancreatic cancer patients. At present, there are still many problems to be solved, such as formulating the principles and standards for the application of radioactive particle implantation in the comprehensive treatment of pancreatic cancer; We will continue to standardize and optimize the operation process and distribution means of radioactive seed implantation technology, and better promote 125I radioactive seed implantation technology.
Abstract: Pancreatic cancer is a digestive system tumor with high degree of malignancy. At present, systemic chemotherapy is the main treatment method. However, due to the difficulty in early diagnosis and easy spread of pancreatic cancer, the survival cycle of patients is short and the treatment effect is poor. 125I seed brachytherapy has obvious advantages...
Show More
-
The Role of DLL4-Notch-VEGFR2 Signaling Pathway in Tumor Angiogenesis
Jie Zhou,
Xinxin Duan,
Ting Xiong,
Aixia Sui
Issue:
Volume 10, Issue 2, June 2022
Pages:
46-50
Received:
3 June 2022
Accepted:
17 June 2022
Published:
27 June 2022
Abstract: Tumor angiogenesis is the center of tumor growth and metastasis, and it increases the supply of nutrients and oxygen to tumors, thereby supporting tumor growth and progression. Vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis and also plays a key role in the process of angiogenesis. Overexpression of VEGF is associated with tumor angiogenesis, promotion of tumor growth and reduced survival rate of patients. Notch signaling is a key pathway that regulates the response to angiogenesis stimulation during embryonic vascular development and postnatal angiogenesis, and is involved in multiple steps of angiogenesis. Dll4 is the only Notch ligand mainly expressed in endothelial cells, which can propagate by activating Notch signal and regulate tumor angiogenesis. Notch signaling pathway and VEGF pathway have both independent and synergistic effects, and Notch is necessary for VEGF-mediated vascular remodeling. The pathways cross each other and jointly regulate tumor angiogenesis. This review reviews the relationship between dLL4-notch-VEGFR2 signaling pathway composition, transduction and regulation and tumor angiogenesis. Combined blocking of DLL4-notch-VEGFR2 signaling pathway can significantly reduce vascular perfusion, resulting in vascular degeneration and reduced tumor survival. It can destroy the vascular system and survival ability of the primary tumor more than blocking alone, thus providing a new idea for the treatment of tumor, which is of great significance for the future anti-angiogenesis therapy.
Abstract: Tumor angiogenesis is the center of tumor growth and metastasis, and it increases the supply of nutrients and oxygen to tumors, thereby supporting tumor growth and progression. Vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis and also plays a key role in the process of angiogenesis. Overexpression of VEGF is associated with...
Show More
-
Warthin Tumor of Parotid Gland Complicated with Hyperhematuria Amylase: A Case Report and Literature Review
Leiqing Bu,
Yupeng Yang,
Huan Mi,
Chenyu Zhang,
Jianqi Gu
Issue:
Volume 10, Issue 2, June 2022
Pages:
51-54
Received:
3 June 2022
Accepted:
17 June 2022
Published:
27 June 2022
Abstract: Clinically, there are many reasons for the elevation of hematuria amylase, the most common being mumps and acute pancreatitis, but it is rare for parotid gland masses to be associated with elevated hematuria amylase. Reading the literature, it can be found that there are few reports about parotid gland tumors and increased hematuria amylase. Most of them are about CT, puncture and clinical manifestation treatment of Worsing tumor. There are reports about this, but most of them are early and clinical cases are few. In this paper, the common causes of increased hematuria amylase in other tumors, mumps and pancreatitis were excluded by a case of parotid gland tumor with increased hematuria amylase. after rule out a common cause of blood in the urine amylase increases. We explored whether hematuria amylase production was caused by the tumor itself, or whether the location of the tumor was particularly pressing the parotid duct, and the excretion of the conducting amylase was blocked into the blood, resulting in increased amylase, or whether it was the result of both. At present, there is no conclusion for parotid gland tumor with increased hematuria amylase, hoping to provide a new idea for the future cause of increased hematuria amylase, so as to provide help for clinical work.
Abstract: Clinically, there are many reasons for the elevation of hematuria amylase, the most common being mumps and acute pancreatitis, but it is rare for parotid gland masses to be associated with elevated hematuria amylase. Reading the literature, it can be found that there are few reports about parotid gland tumors and increased hematuria amylase. Most o...
Show More
